Anti-VEGF Injections for Macular Degeneration: A Patient Guide
Understanding Anti-VEGF Therapy
Anti-VEGF injections are the primary treatment for wet age-related macular degeneration (AMD), a condition that can cause rapid and significant vision loss if left untreated. These targeted medications work by blocking the growth of abnormal blood vessels beneath the retina, helping to preserve and often improve your sight. According to the American Academy of Ophthalmology, intravitreal anti-VEGF therapy has become the standard of care for wet AMD, with clinical trials such as MARINA and ANCHOR demonstrating that roughly 90% of treated patients can maintain vision and approximately one-third experience significant visual improvement (AAO, 2022). At Greenwich Ophthalmology Associates, our retina specialists use the latest anti-VEGF therapies to provide individualized care for patients throughout the greater NY/CT region.
Vascular endothelial growth factor (VEGF) is a protein your body naturally produces to stimulate the growth of new blood vessels. In healthy tissue, VEGF plays a helpful role in healing. In wet AMD, however, the body overproduces VEGF beneath the retina, triggering the growth of fragile, abnormal blood vessels. These vessels leak fluid and blood into the macula, the central part of the retina responsible for sharp, detailed vision. Left unchecked, the leaking damages retinal cells and leads to permanent central vision loss.
Anti-VEGF medications are administered as intravitreal injections, meaning they are placed directly into the vitreous, the gel-like substance that fills the eye. This delivery method allows the medication to reach the retina at a high concentration. Before each injection, your eye is thoroughly numbed with anesthetic drops, and the surface is cleaned with an antiseptic solution to minimize infection risk. The injection itself is performed with a very fine needle and typically takes only a few seconds.
Conditions Treated with Anti-VEGF Therapy
While this guide focuses on wet AMD, anti-VEGF injections are also used to treat several other retinal conditions including diabetic macular edema, proliferative diabetic retinopathy, retinal vein occlusion, and myopic choroidal neovascularization. If you have been diagnosed with dry macular degeneration, it is important to know that dry AMD does not require anti-VEGF injections. However, dry AMD can sometimes convert to the wet form, which is why regular monitoring is essential.
Anti-VEGF therapy targets the underlying cause of wet AMD rather than simply managing symptoms, making it the most effective treatment available today. When injected into the eye, anti-VEGF medications bind to VEGF proteins and prevent them from attaching to receptors on blood vessel cells. This stops the signal that tells the body to grow new, abnormal vessels beneath the retina. By halting this process, the medication helps prevent further leakage and bleeding.
In addition to stopping new vessel growth, anti-VEGF treatment reduces the fluid that has already accumulated under and within the retina. As the abnormal vessels become less leaky, swelling in the macula decreases. Our retina specialists track this fluid reduction using optical coherence tomography (OCT) imaging at each visit. Many patients notice improved clarity and reduced distortion as retinal fluid resolves. Using an Amsler grid to monitor your vision at home can help you detect changes between appointments.
Anti-VEGF Medications for Wet AMD
Several anti-VEGF medications are currently available, and our retina specialists select the best option based on your specific condition, treatment response, and overall health. Bevacizumab (Avastin) was originally developed as a cancer treatment and is used off-label for wet AMD. It is the most affordable anti-VEGF option and has been widely studied, with large clinical trials demonstrating visual outcomes comparable to other agents. Bevacizumab is typically administered every four to six weeks and remains a common first-line choice. Ranibizumab (Lucentis) was the first anti-VEGF medication specifically designed and FDA-approved for wet AMD. It is a smaller antibody fragment engineered to penetrate retinal tissue effectively. Ranibizumab is typically given monthly or on a treat-and-extend schedule, and it has a long track record of safety and efficacy.
Aflibercept (Eylea and Eylea HD) binds to multiple forms of VEGF and to a related protein called placental growth factor, providing broader blockade. The standard formulation is typically given every four to eight weeks after initial monthly loading doses. A higher-dose version, Eylea HD (aflibercept 8 mg), was developed to extend dosing intervals further, with some patients able to go up to 12 to 16 weeks between injections while maintaining stable vision.
Faricimab (Vabysmo) is the first anti-VEGF therapy that targets two pathways involved in wet AMD. In addition to blocking VEGF-A, it also inhibits angiopoietin-2 (Ang-2), a protein that contributes to blood vessel instability and inflammation. Clinical trials showed that many patients treated with faricimab could extend their treatment intervals to every 12 to 16 weeks. Brolucizumab (Beovu) is a smaller anti-VEGF molecule that allows for a higher drug concentration per injection and has demonstrated strong fluid-drying ability.
Treatment Frequency and Schedule
Treatment frequency is tailored to each patient based on how the eye responds. Most treatment plans begin with a loading phase of monthly injections, typically three to four doses given four weeks apart. This initial series is designed to achieve maximum VEGF suppression and dry the retina quickly. Consistent attendance during the loading phase is important because it sets the foundation for your long-term treatment response.
After the loading phase, your treatment frequency is adjusted based on how your retina responds. Approaches include fixed-interval dosing on a set schedule, treat-and-extend dosing where intervals are gradually lengthened as the retina remains dry, and as-needed dosing where injections are given only when signs of active disease return. Treat-and-extend is the most widely used approach among retina specialists today because it balances effective disease control with fewer office visits over time.
Wet AMD is a chronic condition, and skipping or delaying injections can allow fluid to return and cause additional retinal damage. Each visit includes an OCT scan and a clinical examination so your doctor can assess whether the current interval is appropriate. Patients who maintain their treatment schedule tend to have better long-term visual outcomes. Understanding your AMD risk factors and staying on top of your overall health also supports treatment success.
Frequently Asked Questions
Most patients are surprised by how little discomfort they feel. Before the injection, numbing drops are applied to the eye, and some doctors also use a small amount of anesthetic gel or a lidocaine-soaked pledget on the injection site. You may feel brief pressure during the injection, but sharp pain is uncommon. Any mild soreness or grittiness after the procedure typically resolves within a day.
Anti-VEGF injections are considered safe, but as with any procedure, risks exist. The most serious but rare complication is endophthalmitis, an infection inside the eye that occurs in fewer than 1 in 2,000 injections. Other uncommon risks include temporarily elevated eye pressure, retinal detachment, and vitreous hemorrhage. Mild side effects such as eye redness, small floaters, or a scratchy sensation are more common and usually resolve on their own.
A typical appointment lasts about 30 to 60 minutes from check-in to completion, though the injection itself takes only seconds. Most of the visit involves checking your vision, performing OCT imaging, and preparing the eye with numbing and antiseptic drops. You can usually return to most normal activities the same day, though you should avoid rubbing your eye and may want to arrange a ride home.
Many patients notice an improvement in central vision clarity within the first few weeks of starting treatment, particularly as retinal fluid decreases. About 90 percent of patients can maintain their current level of vision with ongoing therapy, and roughly 30 to 40 percent experience meaningful visual improvement. Results vary depending on the severity of disease at diagnosis, how quickly treatment was started, and your adherence to the recommended injection schedule. Incorporating a nutrient-rich diet that supports macular health may complement your treatment plan.
Treat-and-extend is a personalized dosing strategy where you receive an injection at every visit, but the time between visits is gradually increased as long as your retina stays dry and stable. If fluid returns when the interval is extended too far, your doctor shortens the gap by a couple of weeks to find your ideal treatment frequency. This approach reduces the total number of injections and office visits while keeping your disease well controlled.
Stopping treatment abruptly is generally not recommended, because wet AMD is a chronic condition that tends to recur when VEGF is no longer being suppressed. Some patients on extended treatment intervals may eventually reach a point where injections are spaced many months apart, and a small number may be able to pause treatment under close monitoring. This decision should always be made in partnership with your retina specialist based on your imaging results and disease activity.
Protect Your Vision with Expert Retina Care
Anti-VEGF therapy has transformed the outlook for patients with wet macular degeneration, and receiving treatment from fellowship-trained retina specialists gives you the best opportunity for preserving your sight. Understanding how these injections work, what to expect during treatment, and the options available to you can help you feel more confident as you begin or continue your care. Starting treatment promptly after diagnosis typically offers the best chance of preserving the sharpest vision possible.
At Greenwich Ophthalmology Associates, we combine advanced diagnostic imaging with personalized treatment plans to help every patient achieve the best possible visual outcome. The degree of improvement depends on factors such as how early treatment begins, the extent of retinal damage already present, and how consistently you receive scheduled injections. If you have been diagnosed with wet AMD or have noticed changes in your central vision, scheduling an evaluation is an important first step toward protecting the vision you rely on every day. For patients also managing cataracts, our team can coordinate care through appropriate cataract surgical planning.
What our Patients say
4.8
Reviews
(3,408)